Differentiation of malignant lymphoma and non-lymphoma by an occlusive dressing method employing bromodeoxyuridine

Area of Science:

• Dermatology
• Oncology
• Immunology

Background:

• Lymphoma cells proliferate in skin, unlike benign lymphocytes in inflammatory conditions.
• Differentiating malignant lymphomas from benign lymphocytic infiltrations is crucial for patient prognosis.
• Cell cycle-related antigens can potentially distinguish between these conditions.

Purpose of the Study:

• To develop and validate a novel in vivo method for assessing human skin lymphoid cell kinetics.
• To differentiate malignant cutaneous lymphomas from benign lymphocytic infiltrations using bromodeoxyuridine (BrdU) labeling.
• To evaluate the potential of this method in aiding prognostic determination for skin lymphomas.

Main Methods:

• Developed an in vivo method using bromodeoxyuridine (BrdU) with occlusive dressings for human skin cell kinetics.
• Applied BrdU-containing occlusive plasters to skin specimens from patients with lymphomas and inflammatory skin diseases.
• Quantified BrdU-labeled lymphoid cells in dermal skin specimens via immunostaining with anti-BrdU monoclonal antibody.

Main Results:

• Significantly higher percentages of BrdU-labeled lymphoid cells were observed in the lymphoma group (15.9% ± 7.6%) compared to the non-lymphoma group (4.7% ± 2.6%).
• The difference in labeled cell percentages between the lymphoma and non-lymphoma groups was statistically significant (p < 0.0001).
• The BrdU labeling method demonstrated efficacy in distinguishing malignant lymphomas from benign lymphocytic infiltrations.

Conclusions:

• The novel in vivo BrdU labeling method effectively differentiates malignant lymphomas from benign lymphocytic infiltrations in human skin.
• Counting BrdU-labeled lymphoid cells provides a reliable means to distinguish between these conditions.
• This technique holds promise for improving the diagnostic accuracy and prognostic assessment of cutaneous lymphomas.